Repligen (RGEN) PT Raised to $135 at Stifel
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $180.81 +2.52%
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 20
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 20
Join SI Premium – FREE
Stifel analyst Daniel Arias raised the price target on Repligen (NASDAQ: RGEN) to $135.00 (from $113.00) while maintaining a Buy rating.
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Edgewise Therapeutics (EWTX) PT Raised to $60 at JPMorgan
- Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
